Corticosteroid-induced hyperglycemia

Detalhes bibliográficos
Autor(a) principal: Ferreira, Yasmim Berni
Data de Publicação: 2024
Outros Autores: Júca Neto, José de Ribamar Barroso, Duarte Filho, Fernando Barroso, Vasconcelos, Fernanda Alice Silva, Mesquita, Raian Oliveira, Campelo, Ana Paula Bomfim Soares, Campelo, Marcio Wilker Soares
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/44900
Resumo: Glucocorticoids are medications of wide medical use, notably due to their known anti-inflammatory effects. Furthermore, fluctuations in glycemic indexes stand out as risk factors for clinical and surgical complications, mortality and increased hospital stay. The study consists of an integrative and descriptive literature review, through the PUBMED platform with the following keywords: “Hyperglycemia”, “Glucocorticoid” and “Induce”, in the last 12 years and aims to gather and unify information regarding the understanding and clinical and therapeutic management of hyperglycemia induced by the use of corticosteroids and corticogenic diabetes. The fluctuation in glycemic indexes with the use of corticosteroid therapy is an imbalance between the increase in insulin resistance and the inhibition of insulin production and secretion at the pancreatic cellular level. Screening for Diabetes Mellitus in patients on corticosteroid therapy is based on consensus in the literature with a plasma glucose level above 125 mg/dL, any capillary measurement above 200 mg/dL, HbA1c> 6.5% or oral tolerance test glucose above 200mg/dL after 2 hours. The main glycemic target is capillary blood glucose between 108-180 mg/dL and in cases of initiating therapeutic approaches for hospital management of glycemic fluctuations, the use of insulin therapy is chosen. Hyperglycemia induced by the use of corticosteroids is a topic that has been gaining prominence in the medical scenario, despite the lack of studies that uniformly protocol the approach to patients when this scenario is confirmed, with the aim of reducing the risks associated with hospitalization.
id UNIFEI_c5e13a8b266e7ef1e49c7be48846af93
oai_identifier_str oai:ojs.pkp.sfu.ca:article/44900
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Corticosteroid-induced hyperglycemiaHiperglucemia inducida por corticosteroidesHiperglicemia induzida por corticosteroidesHiperglucemiaDiabetes MellitusCorticoesteroides.HyperglycemiaDiabetes MellitusAdrenal cortex hormones.HiperglicemiaDiabetes MellitusCorticoesteroides.Glucocorticoids are medications of wide medical use, notably due to their known anti-inflammatory effects. Furthermore, fluctuations in glycemic indexes stand out as risk factors for clinical and surgical complications, mortality and increased hospital stay. The study consists of an integrative and descriptive literature review, through the PUBMED platform with the following keywords: “Hyperglycemia”, “Glucocorticoid” and “Induce”, in the last 12 years and aims to gather and unify information regarding the understanding and clinical and therapeutic management of hyperglycemia induced by the use of corticosteroids and corticogenic diabetes. The fluctuation in glycemic indexes with the use of corticosteroid therapy is an imbalance between the increase in insulin resistance and the inhibition of insulin production and secretion at the pancreatic cellular level. Screening for Diabetes Mellitus in patients on corticosteroid therapy is based on consensus in the literature with a plasma glucose level above 125 mg/dL, any capillary measurement above 200 mg/dL, HbA1c> 6.5% or oral tolerance test glucose above 200mg/dL after 2 hours. The main glycemic target is capillary blood glucose between 108-180 mg/dL and in cases of initiating therapeutic approaches for hospital management of glycemic fluctuations, the use of insulin therapy is chosen. Hyperglycemia induced by the use of corticosteroids is a topic that has been gaining prominence in the medical scenario, despite the lack of studies that uniformly protocol the approach to patients when this scenario is confirmed, with the aim of reducing the risks associated with hospitalization.Los glucocorticoides son medicamentos de amplio uso médico, especialmente por sus conocidos efectos antiinflamatorios. Además, las fluctuaciones en los índices glucémicos se destacan como factores de riesgo de complicaciones clínicas, quirúrgicas, mortalidad y aumento de la estancia hospitalaria. El estudio consiste en una revisión integrativa y descriptiva de la literatura, a través de la plataforma PUBMED con las siguientes palabras clave: “Hiperglucemia”, “Glucocorticoide” e “Induce”, en los últimos 12 años, y tiene como objetivo reunir y unificar la información sobre la comprensión y el manejo clínico y terapéutico de la hiperglucemia inducida por el uso de corticosteroides y la diabetes corticogénica. La fluctuación de los índices glucémicos con el uso de la terapia con corticosteroides es un desequilibrio entre el aumento de la resistencia a la insulina y la inhibición de la producción y secreción de insulina a nivel celular pancreático. El cribado de Diabetes Mellitus en pacientes en tratamiento con corticoides se basa en el consenso de la literatura con un nivel de glucosa plasmática superior a 125 mg/dL, cualquier medición capilar superior a 200 mg/dL, HbA1c > 6,5% o prueba de tolerancia oral a la glucosa superior a 200 mg/dL después 2 horas. El principal objetivo glucémico es la glucemia capilar entre 108-180 mg/dL y en los casos de iniciar abordajes terapéuticos para el manejo hospitalario de las fluctuaciones glucémicas se opta por el uso de terapia con insulina. La hiperglucemia inducida por el uso de corticoides es un tema que viene ganando protagonismo en el escenario médico, a pesar de la falta de estudios que protocolicen de manera uniforme el abordaje de los pacientes cuando se confirma este escenario, con el objetivo de reducir los riesgos asociados a la hospitalización.Glicocorticóides são medicações de amplo uso médico, destacadamente, por seus efeitos conhecidos de ação anti-inflamatória. Acresça-se que, destaca-se as oscilações dos índices glicêmicos como fatores de risco para complicações clínicas e cirúrgicas, mortalidade e aumento da permanência hospitalar. O estudo consiste em uma revisão de literatura integrativa e descritiva, por meio da plataforma PUBMED com as seguintes palavras-chaves: “Hyperglicemia”, “Glucocorticoid” e “Induce”, nos últimos 12 anos, e tem como objetivo reunir e unificar as informações acerca do entendimento e do manejo clínico e terapêutico sobre a hiperglicemia induzida pelo uso de corticoesteroides e a diabetes corticogênica. A oscilação dos índices glicêmicos com uso de corticoterapia é um desbalanço entre o aumento da resistência insulínica e a inibição da produção e da secreção da insulina em nível celular pancreático. O rastreio de Diabetes Mellitus em pacientes em corticoterapia é feito a partir de consenso entre literatura com nível de glicose plasmática acima de 125 mg/dL, qualquer medida capilar acima de 200 mg/dL, HbA1c> 6,5% ou teste oral de tolerância à glicose acima de 200mg/dL após 2 horas. A principal meta glicêmica é uma glicemia capilar entre 108-180 mg/dL e nos casos de iniciar condutas terapêuticas para manejo hospitalar das oscilações glicêmicas opta-se pelo uso de insulinoterapia. A hiperglicemia induzida pelo uso de corticoesteroides é um tema que vem ganhando destaque no cenário médico, apesar de carecer estudos que protocolem uniformemente a abordagem dos pacientes quando esse cenário for confirmado, com o objetivo de diminuir os riscos associados ao internamento.Research, Society and Development2024-01-31info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/4490010.33448/rsd-v13i1.44900Research, Society and Development; Vol. 13 No. 1; e14813144900Research, Society and Development; Vol. 13 Núm. 1; e14813144900Research, Society and Development; v. 13 n. 1; e148131449002525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/44900/35868Copyright (c) 2024 Yasmim Berni Ferreira; José de Ribamar Barroso Júca Neto; Fernando Barroso Duarte Filho; Fernanda Alice Silva Vasconcelos; Raian Oliveira Mesquita; Ana Paula Bomfim Soares Campelo; Marcio Wilker Soares Campelohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessFerreira, Yasmim Berni Júca Neto, José de Ribamar Barroso Duarte Filho, Fernando Barroso Vasconcelos, Fernanda Alice Silva Mesquita, Raian OliveiraCampelo, Ana Paula Bomfim Soares Campelo, Marcio Wilker Soares 2024-02-01T09:48:39Zoai:ojs.pkp.sfu.ca:article/44900Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-02-01T09:48:39Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Corticosteroid-induced hyperglycemia
Hiperglucemia inducida por corticosteroides
Hiperglicemia induzida por corticosteroides
title Corticosteroid-induced hyperglycemia
spellingShingle Corticosteroid-induced hyperglycemia
Ferreira, Yasmim Berni
Hiperglucemia
Diabetes Mellitus
Corticoesteroides.
Hyperglycemia
Diabetes Mellitus
Adrenal cortex hormones.
Hiperglicemia
Diabetes Mellitus
Corticoesteroides.
title_short Corticosteroid-induced hyperglycemia
title_full Corticosteroid-induced hyperglycemia
title_fullStr Corticosteroid-induced hyperglycemia
title_full_unstemmed Corticosteroid-induced hyperglycemia
title_sort Corticosteroid-induced hyperglycemia
author Ferreira, Yasmim Berni
author_facet Ferreira, Yasmim Berni
Júca Neto, José de Ribamar Barroso
Duarte Filho, Fernando Barroso
Vasconcelos, Fernanda Alice Silva
Mesquita, Raian Oliveira
Campelo, Ana Paula Bomfim Soares
Campelo, Marcio Wilker Soares
author_role author
author2 Júca Neto, José de Ribamar Barroso
Duarte Filho, Fernando Barroso
Vasconcelos, Fernanda Alice Silva
Mesquita, Raian Oliveira
Campelo, Ana Paula Bomfim Soares
Campelo, Marcio Wilker Soares
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Ferreira, Yasmim Berni
Júca Neto, José de Ribamar Barroso
Duarte Filho, Fernando Barroso
Vasconcelos, Fernanda Alice Silva
Mesquita, Raian Oliveira
Campelo, Ana Paula Bomfim Soares
Campelo, Marcio Wilker Soares
dc.subject.por.fl_str_mv Hiperglucemia
Diabetes Mellitus
Corticoesteroides.
Hyperglycemia
Diabetes Mellitus
Adrenal cortex hormones.
Hiperglicemia
Diabetes Mellitus
Corticoesteroides.
topic Hiperglucemia
Diabetes Mellitus
Corticoesteroides.
Hyperglycemia
Diabetes Mellitus
Adrenal cortex hormones.
Hiperglicemia
Diabetes Mellitus
Corticoesteroides.
description Glucocorticoids are medications of wide medical use, notably due to their known anti-inflammatory effects. Furthermore, fluctuations in glycemic indexes stand out as risk factors for clinical and surgical complications, mortality and increased hospital stay. The study consists of an integrative and descriptive literature review, through the PUBMED platform with the following keywords: “Hyperglycemia”, “Glucocorticoid” and “Induce”, in the last 12 years and aims to gather and unify information regarding the understanding and clinical and therapeutic management of hyperglycemia induced by the use of corticosteroids and corticogenic diabetes. The fluctuation in glycemic indexes with the use of corticosteroid therapy is an imbalance between the increase in insulin resistance and the inhibition of insulin production and secretion at the pancreatic cellular level. Screening for Diabetes Mellitus in patients on corticosteroid therapy is based on consensus in the literature with a plasma glucose level above 125 mg/dL, any capillary measurement above 200 mg/dL, HbA1c> 6.5% or oral tolerance test glucose above 200mg/dL after 2 hours. The main glycemic target is capillary blood glucose between 108-180 mg/dL and in cases of initiating therapeutic approaches for hospital management of glycemic fluctuations, the use of insulin therapy is chosen. Hyperglycemia induced by the use of corticosteroids is a topic that has been gaining prominence in the medical scenario, despite the lack of studies that uniformly protocol the approach to patients when this scenario is confirmed, with the aim of reducing the risks associated with hospitalization.
publishDate 2024
dc.date.none.fl_str_mv 2024-01-31
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/44900
10.33448/rsd-v13i1.44900
url https://rsdjournal.org/index.php/rsd/article/view/44900
identifier_str_mv 10.33448/rsd-v13i1.44900
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/44900/35868
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 13 No. 1; e14813144900
Research, Society and Development; Vol. 13 Núm. 1; e14813144900
Research, Society and Development; v. 13 n. 1; e14813144900
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052637406822400